Biotech, Food & Drug

HB Ad Slot
HB Mobile Ad Slot

In today’s hyper-aware environment, concerns about food and drug safety are paramount for both companies and consumers.  The Food and Drug Administration (FDA) and the US Department of Agriculture (USDA) regulates the areas of biotech, food, and drug law. Additionally, laws including the 21st Century Cures Act, and cGMP (Current Good Manufacturing Processes), regulate industry standards/norms in food, cosmetics, and other industry-sectors. Visitors to the National Law Review will find the latest analysis of news, legislation, and upcoming cases/litigation as it relates to this area of law.

With researchers searching for new energy solutions and other developments in biotech, visitors to the NLR will have the opportunity to read content surrounding biosimilars, natural fuel production, medical devices, biotechnology, nanotechnology and materials, and the pharmaceuticals industry. Additionally, content relating to food and drug laws, limits on chemical use in cosmetic products, and other general health/safety topics are covered by the National Law Review and are updated regularly. Additionally, food safety and imports to the United States are also discussed as they become relevant. 

In addition to general health, science, and food/drug, the industry is also closely related to many of the issues related to intellectual property law. New applications for patents, intellectual property, licensing laws, and other areas which are governed by the PTAB court, often crossover into the industry.

New developments in legislation, including the legalization of recreational marijuana has created a new area ripe for legal analysis.  Regulations on how recreational marijuana can be advertised and marketed, distributed and the kind of insurance coverage necessary for dispensaries.  Additionally, employer drug-testing and marijuana statutes have been a hot area of litigation covered by the National Law Review.  

General practices in marketing standards, compliance of federal and state laws/legislation, licensing collaborations, and news related to bringing new products to the market, in the US and abroad, are among the areas visitors to NLR will read about daily. Drug pricing, changes in production standards, regulatory compliance, food safety and handling, drug laws (legalization of marijuana, both recreational and medicinal in the workplace), and labeling and nutritional requirements, are among the many topics covered by the National Law Review daily.

Visitors will always find the latest, up-to-date, most comprehensive coverage on the site. And, news and stories which affect the US, companies which are regulated in the industry, and multinational/international companies, are detailed regularly for NLR readers.

National Law Review Cannabis TwitterFor hourly updates on the latest news about biotech, food & drug, and cannabis laws, regulations, and legislation, be sure to follow our Cannabis X (formerly Twitter) feed, and sign up for complimentary e-news bulletins.

Recent Biotechnology, Food & Drug Administration FDA News

Title
Publication Date Organization Sort ascending
Nov
10
2023
Trending in Telehealth: November 1 – 7, 2023 McDermott Will & Emery
Dec
8
2023
Illinois Supreme Court: Finger-Scan Information Collected by Healthcare Providers to Access Medications Is Exempt From BIPA Liability McDermott Will & Emery
Dec
14
2023
If the Label Is Skinny Enough – No Inducement Under Hatch-Waxman McDermott Will & Emery
Jan
19
2024
This Week in 340B: January 9 – 16, 2024 McDermott Will & Emery
Sep
29
2016
FDA Issues Draft Guidance on Risk Evaluation and Mitigation Strategy (REMS) Determinations McDermott Will & Emery
Jun
10
2020
Fee Shifting Under § 285 Does Not Apply to Conduct Solely Arising in IPR McDermott Will & Emery
Aug
24
2020
HSS Rescinds FDA's "Informal" Ability to Require Premarket Review pf LDTS Without Formal Rulemaking McDermott Will & Emery
Apr
24
2024
Trending in Telehealth: March 26 – April 1, 2024 McDermott Will & Emery
Dec
21
2020
An Early Holiday Present for Generics? Legislation Requiring Greater Disclosure by Brands Passes the Senate McDermott Will & Emery
Jan
11
2021
HHS Advisory Opinion Concludes Manufacturers Must Deliver 340 B Drugs to Contract Pharmacies McDermott Will & Emery
Jun
26
2017
RICO Madness: Marijuana Operations Face RICO Challenges in Federal Courts McDermott Will & Emery
Sep
29
2017
FDA Proposes to Extend Compliance Dates for Nutrition and Supplement Facts Labels and Serving Size McDermott Will & Emery
Dec
12
2017
FDA Issues Fourth and Final Software as a Medical Device Clinical Evaluation Guidance McDermott Will & Emery
Dec
26
2011
Broad Scope and Impact of California “Green Chemistry” Regulations McDermott Will & Emery
Jul
9
2012
What Is an “Abstract Idea”? Who’s on First? What’s on Second? McDermott Will & Emery
Jan
4
2013
Key Energy Tax Provisions Included in ‘Fiscal Cliff’ Legislation McDermott Will & Emery
Jun
9
2021
Video: Leaders Moving Business Forward with Peter Mason of UNICEF McDermott Will & Emery
Mar
9
2013
International Trade Actions Complicate Global Market For Renewable Energy Businesses, Particularly Solar Sector McDermott Will & Emery
Jun
1
2013
Patent Exhaustion Rejected: Patented Seed Purchaser Has No Right to Make Copies McDermott Will & Emery
Sep
9
2021
Another Genus Claim Bites the Dust for Lack of Written Description McDermott Will & Emery
Jun
30
2013
Generic Versions of AstraZeneca’s Pulmicort Respules Enjoined from Launch Pending Appeal in Patent Infringement Case McDermott Will & Emery
Aug
8
2013
Acquiring Italian Distressed Renewable Energy Assets McDermott Will & Emery
Nov
4
2021
Standing Challenge Brews Trouble in Trademark Dispute McDermott Will & Emery
Sep
6
2013
Department of Energy (DOE) Announces Funding for Hydrokinetic Power Projects McDermott Will & Emery
Jan
24
2014
Massachusetts DOER (Department of Energy Resources) Proposes to Expand to 1600 MW Generation Eligible to Create SRECs (Solar Carve-Out II Program) McDermott Will & Emery
Mar
8
2022
FDA Issues Final Guidance for Initiation of Voluntary Recalls McDermott Will & Emery
Mar
26
2014
D.C. Circuit Denies Rehearing on Nuclear Waste Fee Decision McDermott Will & Emery
Apr
17
2014
The President’s Methane Reduction Strategy – Here’s What Energy Companies Need to Know McDermott Will & Emery
 

NLR Logo

We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up to receive our free e-Newsbulletins

 

Sign Up for e-NewsBulletins